Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer

Abstract Background Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) is now recommended as a first-line staging modality in prostate cancer patients, and the widespread use of DWIBS may lead to an increased frequency of incidental findings. The aim of this study is to evaluate the prevalence and clinical significance of incidental findings detected on whole-body magnetic resonance imaging (WB-MRI) with DWIBS in patients with prostate cancer. Methods Data from 124 patients (age, 76.5 ± 5.6 years; range, 60–90) with pathologically confirmed prostate cancer, who underwent WB-MRI between December 2016 and April 2020, were retrospectively analyzed. Findings unrelated to prostate cancer were considered as incidental findings and categorized into two groups based on their clinical implications, as follow: imaging follow-up or additional examinations was required (significant incidental findings) and no need to additional work-up (non-significant incidental findings). A Chi-square test was performed to compare the differences in the prevalence of significant incidental findings based on age (≤ 75 and > 75 years old). Results A total of 334 incidental findings were found, with 8.1% (n = 27) as significant incidental findings and 91.9% (n = 307) as non-significant incidental findings. Significant incidental findings were more frequent in patients over 75 years old than those of 75 years old or younger (28.6% vs 11.1%, p = 0.018). Nineteen of the 27 significant incidental findings (70.4%) were observed on non-DWIBS sequences. Conclusion Clinically significant incidental findings, which required imaging follow-up or additional examinations, were commonly observed in patients with prostate cancer on WB-MRI/DWIBS.

Download Full-text

Whole-body magnetic resonance imaging for detecting bone metastases: comparison with bone scintigraphy

La radiologia medica ◽

10.1007/s11547-008-0341-y ◽

2008 ◽

Vol 113 (8) ◽

pp. 1157-1170 ◽

Cited By ~ 11

Author(s):

G. Cascini ◽

C. Falcone ◽

C. Greco ◽

B. Bertucci ◽

S. Cipullo ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Bone Metastases ◽

Bone Scintigraphy ◽

Whole Body ◽

Resonance Imaging ◽

Body Magnetic Resonance Imaging

Download Full-text

Whole-body magnetic resonance imaging (WB-MRI) with diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) in prostate cancer: Prevalence and clinical significance of incidental findings

British Journal of Radiology ◽

10.1259/bjr.20210459 ◽

2021 ◽

pp. 20210459

Author(s):

Soma Kumasaka ◽

Shunichi Motegi ◽

Yuka Kumasaka ◽

Tatsuya Nishikata ◽

Masami Otomo ◽

...

Keyword(s):

Prostate Cancer ◽

Incidental Findings ◽

Whole Body ◽

Whole Body Imaging ◽

Resonance Imaging ◽

Body Imaging ◽

Signal Suppression ◽

Body Magnetic Resonance Imaging ◽

Clinically Significant

Objective: Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) is now recommended as a first-line staging modality in prostate cancer patients, and the widespread use of DWIBS may lead to an increased frequency of incidental findings. The aim of this study was to evaluate the prevalence and clinical significance of incidental findings on whole-body magnetic resonance imaging (WB-MRI) with DWIBS. Methods: Data from 124 patients with prostate cancer (age, 76.5 ± 5.6 years), who underwent 1.5 T WB-MRI with STIR, TSE-T2, TSE-T1, In/Out GRE, and DWIBS sequences, were retrospectively analyzed. Findings unrelated to prostate cancer were considered as incidental findings and categorized into two groups based on their clinical implications, as follow: imaging follow-up or additional examinations was required (significant incidental findings) and no need to additional work-up (non-significant incidental findings). A Chi-square test was performed to compare the differences in the prevalence of significant incidental findings based on age (≤75 and>75 years old). Results: A total of 334 incidental findings were found, with 8.1% (n = 27) as significant incidental findings. Significant incidental findings were more frequent in patients over 75 years old than those of 75 years old or younger (28.6% vs 11.1%, p = 0.018). Conclusion: Clinically significant incidental findings, which required imaging follow-up or additional examinations, were commonly observed in prostate cancer patients on WB-MRI/DWIBS. Advances in knowledge: Some incidental findings were clinically significant which may lead to changes in treatment strategy. Checking the entire organ carefully for abnormalities, and reporting any incidental findings detected are important.

Download Full-text

Faculty Opinions recommendation of Whole-body magnetic resonance imaging for detecting bone metastases: comparison with bone scintigraphy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.2082972.1671070 ◽

2010 ◽

Author(s):

Maria Cova ◽

Emilio Quaia

Keyword(s):

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Bone Metastases ◽

Bone Scintigraphy ◽

Whole Body ◽

Resonance Imaging ◽

Body Magnetic Resonance Imaging

Download Full-text

Clinical significance of diffusion-weighted whole body magnetic resonance imaging with background body signal suppression (DWIBS) as a staging procedure for lymphoma patients in comparison with FDG-PET

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.8084 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 8084-8084

Author(s):

T. Itoyama ◽

T. Shibuya ◽

T. Koga ◽

M. Kitagawa ◽

T. Yoshida ◽

...

Keyword(s):

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Clinical Significance ◽

Fdg Pet ◽

Clinical Staging ◽

Whole Body ◽

Resonance Imaging ◽

Diffusion Weighted ◽

Signal Suppression ◽

Body Magnetic Resonance Imaging

8084 Background: FDG-PET is thought to be an important staging tool in lymphomas. However, high cost and exposure to radioactive agents are of disadvantage. Diffusion weighted whole body magnetic resonance imaging with background body signal suppression (DWIBS) is recently reported to be a new way of magnetic resonance imaging which can make FDG-PET-like imaging possible to detect tumors (Takahara et al; Radiation Medicine 22: 275–282, 2004). This study is aimed to compare accuracy and clinical significance of DWIBS to FDG - PET. Methods: We examined 19 lymphoma (Ly) patients (pts) by using both DWIBS and FDG -PET at the time of diagnosis before therapy. There were follicular Ly in 3 pts, nodal marginal zone Ly in 1, diffuse large B-cell Ly in 9 including primary stomach Ly in 2, peripheral T -cell Ly in 4, and MALT Ly of stomach (GI-MALT) in 2. DWIBS was performed with a 1.5 -Tesla system as previously reported (Ochiai et al; Nichidoku -Iho 50: 86–98, 2005). Clinical staging was made according to the Ann Arbor classification. Results: Both DWIBS and FDG -PET had positive findings in 18 of 19 pts except for a case of GI -MALT. In nodal lesions, DWIBS was positive in 16 pts at 66 sites compared to 16 pts at 68 sites with FDG -PET. DWIBS was negative in 3 pts at 5 sites in spleen, hilar and mediastinal lymphnodes where positive in FDG -PET. DWIBS was positive in 2 pts at 4 sites in iliac and inguinal lymphnodes that are negative in FDG -PET. In extranodal lesions, DWIBS was positive in 12 pts at 17 sites as compared to 12 pts at 18 sites with FDG -PET. Involvement of bone and stomach were equally identified at 8 sites. DWIBS was negative in 2 pts at 2 sites in liver and pleura with FDG -PET positive. Small skin lesions were clearly identified on DWIBS. Discordance of clinical staging was not observed between DWIBS and FDG -PET. Conclusions: Although some discrepancy was seen between DWIBS and FDG -PET, there was no disadvantage of DWIBS compared to FDG -PET. Furthermore, DWIBS has no risk of radiation exposure and is even advantageous to detect lesions with FDG -PET negative. We conclude DWIBS is a new useful tool to assess tumor spread in lymphomas. No significant financial relationships to disclose.

Download Full-text